A Role for Single Agent TKI Therapies in Treating Renal Cell Carcinoma

A panel of oncologists reviews a publication by Robert J. Motzer, MD, and colleagues on data from the CLEAR trial examining lenvatinib plus either pembrolizumab or everolimus for advanced renal cell carcinoma.

Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.

Thought leaders Daniel P. Petrylak, MD; Benjamin H. Lowentritt, MD; Alan H. Bryce, MD; and Tanya Dorff, MD, joined CancerNetwork® following the 2022 Genitourinary Cancers Symposium to discuss highlights of the meeting in a game show–style production.

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

Efficacy of adjuvant mitotane for patients with adrenocortical carcinoma following surgery was presented at 2022 ASCO GU.

At 2022 ASCO GU, early trial results show promise for fluorodeoxyglucose and sodium fluoride PET/CT prognostic ability to predict survival in patients with metastatic genitourinary malignancies treated with cabozantinib plus PD-1/CTLA-3 inhibition.